Molecular and Cellular Biochemistry

, Volume 370, Issue 1–2, pp 199–207 | Cite as

Thioredoxin reductase is inhibited by the carbamoylating activity of the anticancer sulfonylhydrazine drug laromustine

  • Kevin P. RiceEmail author
  • Edmund J. Klinkerch
  • Scott A. Gerber
  • Tyler R. Schleicher
  • Tara J. Kraus
  • Christopher M. Buros


The thioredoxin system facilitates proliferative processes in cells and is upregulated in many cancers. The activities of both thioredoxin (Trx) and its reductase (TrxR) are mediated by oxidation/reduction reactions among cysteine residues. A common target in preclinical anticancer research, TrxR is reported here to be significantly inhibited by the anticancer agent laromustine. This agent, which has been in clinical trials for acute myelogenous leukemia and glioblastoma multiforme, is understood to be cytotoxic principally via interstrand DNA crosslinking that originates from a 2-chloroethylating species generated upon activation in situ. The spontaneous decomposition of laromustine also yields methyl isocyanate, which readily carbamoylates thiols and primary amines. Purified rat liver TrxR was inhibited by laromustine with a clinically relevant IC50 value of 4.65 μM. A derivative of laromustine that lacks carbamoylating activity did not appreciably inhibit TrxR while another derivative, lacking only the 2-chloroethylating activity, retained its inhibitory potency. Furthermore, in assays measuring TrxR activity in murine cell lysates, a similar pattern of inhibition among these compounds was observed. These data contrast with previous studies demonstrating that glutathione reductase, another enzyme that relies on cysteine-mediated redox chemistry, was not inhibited by methylcarbamoylating agents when measured in cell lysates. Mass spectrometry of laromustine-treated enzyme revealed significant carbamoylation of TrxR, albeit not on known catalytically active residues. However, there was no evidence of 2-chloroethylation anywhere on the protein. The inhibition of TrxR is likely to contribute to the cytotoxic, anticancer mechanism of action for laromustine.


Thioredoxin reductase Alkylating agents Methyl isocyanate Laromustine 



This project was supported by grants from the National Center for Research Resources (5P20RR016463-12 to K.P.R. and P20-RR018787 to S.A.G) and the National Institute of General Medical Sciences (8 P20 GM103423-12 to K.P.R.), of the National Institutes of Health, and from the Colby College Division of Natural Sciences. The authors would also like to acknowledge Alan Sartorelli (Yale University School of Medicine) for furnishing the compounds necessary to begin this project. The authors would like to thank Jeffrey Katz and Nicholas Bizer (Colby College) for providing counsel toward the chemical syntheses.


  1. 1.
    Baumann RP, Seow HA, Shyam K, Penketh PG, Sartorelli AC (2005) The antineoplastic efficacy of the prodrug cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation. Oncol Res 15:313–325PubMedGoogle Scholar
  2. 2.
    Finch RA, Shyam K, Penketh PG, Sartorelli AC (2001) 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101 M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Res 61:3033–3038PubMedGoogle Scholar
  3. 3.
    Ishiguro K, Seow HA, Penketh PG, Shyam K, Sartorelli AC (2006) Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine. Mol Cancer Ther 5:969–976PubMedCrossRefGoogle Scholar
  4. 4.
    Penketh PG, Shyam K, Baumann RP, Remack JS, Brent TP, Sartorelli AC (2004) 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazi ne (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition. Cancer Chemother Pharmacol 53:279–287PubMedCrossRefGoogle Scholar
  5. 5.
    Penketh PG, Baumann RP, Ishiguro K, Shyam K, Seow HA, Sartorelli AC (2008) Lethality to leukemia cell lines of DNA interstrand cross-links generated by cloretazine derived alkylating species. Leuk Res 32:1546–1553PubMedCrossRefGoogle Scholar
  6. 6.
    Baumann RP, Shyam K, Penketh PG, Remack JS, Brent TP, Sartorelli AC (2004) 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazi ne (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity. Cancer Chemother Pharmacol 53:288–295PubMedCrossRefGoogle Scholar
  7. 7.
    Frederick AM, Davis ML, Rice KP (2009) Inhibition of human DNA polymerase beta activity by the anticancer prodrug cloretazine. Biochem Biophys Res Commun 378:419–423PubMedCrossRefGoogle Scholar
  8. 8.
    Eisenbrand G, Muller N, Denkel E, Sterzel W (1986) DNA adducts and DNA damage by antineoplastic and carcinogenic N-nitrosocompounds. J Cancer Res Clin Oncol 112:196–204PubMedCrossRefGoogle Scholar
  9. 9.
    Gombar CT, Tong WP, Ludlum DB (1980) Mechanism of action of the nitrosoureas–IV. Reactions of bis-chloroethyl nitrosourea and chloroethyl cyclohexyl nitrosourea with deoxyribonucleic acid. Biochem Pharmacol 29:2639–2643PubMedCrossRefGoogle Scholar
  10. 10.
    Abushamaa AM, Sporn TA, Folz RJ (2002) Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen. Am J Physiol Lung Cell Mol Physiol 283:L336–L345PubMedGoogle Scholar
  11. 11.
    Johnston TP, Montgomery JA (1986) Relationship of structure to anticancer activity and toxicity of the nitrosoureas in animal systems. Cancer Treat Rep 70:13–30PubMedGoogle Scholar
  12. 12.
    Gibson NW, Hickman JA (1982) The role of isocyanates in the toxicity of antitumour haloalkylnitrosoureas. Biochem Pharmacol 31:2795–2800PubMedCrossRefGoogle Scholar
  13. 13.
    Rice KP, Penketh PG, Shyam K, Sartorelli AC (2005) Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs cloretazine and BCNU. Biochem Pharmacol 69:1463–1472PubMedCrossRefGoogle Scholar
  14. 14.
    Slatter JG, Davis MR, Han DH, Pearson PG, Baillie TA (1993) Studies on the metabolic fate of caracemide, an experimental antitumor agent, in the rat. Evidence for the release of methyl isocyanate in vivo. Chem Res Toxicol 6:335–340PubMedCrossRefGoogle Scholar
  15. 15.
    Kestell P, Gledhill AP, Threadgill MD, Gescher A (1986) S-(N-methylcarbamoyl)-N-acetylcysteine: a urinary metabolite of the hepatotoxic experimental antitumour agent N-methylformamide (NSC 3051) in mouse, rat and man. Biochem Pharmacol 35:2283–2286PubMedCrossRefGoogle Scholar
  16. 16.
    Moriarty-Craige SE, Jones DP (2004) Extracellular thiols and thiol/disulfide redox in metabolism. Annu Rev Nutr 24:481–509PubMedCrossRefGoogle Scholar
  17. 17.
    Meister A (1994) Glutathione–ascorbic acid antioxidant system in animals. J Biol Chem 269:9397–9400PubMedGoogle Scholar
  18. 18.
    Smith AC, Boyd MR (1984) Preferential effects of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on pulmonary glutathione reductase and glutathione/glutathione disulfide ratios: possible implications for lung toxicity. J Pharmacol Exp Ther 229:658–663PubMedGoogle Scholar
  19. 19.
    Holmgren A, Bjornstedt M (1995) Thioredoxin and thioredoxin reductase. Methods Enzymol 252:199–208PubMedCrossRefGoogle Scholar
  20. 20.
    Mustacich D, Powis G (2000) Thioredoxin reductase. Biochem J 346(Pt 1):1–8PubMedCrossRefGoogle Scholar
  21. 21.
    Holmgren A, Lu J (2010) Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun 396:120–124PubMedCrossRefGoogle Scholar
  22. 22.
    Powis G, Montfort WR (2001) Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 41:261–295PubMedCrossRefGoogle Scholar
  23. 23.
    Arner ES, Holmgren A (2000) Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267:6102–6109PubMedCrossRefGoogle Scholar
  24. 24.
    Liu Y, Min W (2002) Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res 90:1259–1266PubMedCrossRefGoogle Scholar
  25. 25.
    Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, Ichijo H (1998) Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17:2596–2606PubMedCrossRefGoogle Scholar
  26. 26.
    Pennington JD, Jacobs KM, Sun L, Bar-Sela G, Mishra M, Gius D (2007) Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Curr Pharm Des 13:3368–3377PubMedCrossRefGoogle Scholar
  27. 27.
    Urig S, Becker K (2006) On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol 16:452–465PubMedCrossRefGoogle Scholar
  28. 28.
    Zeng HH, Wang LH (2010) Targeting thioredoxin reductase: anticancer agents and chemopreventive compounds. Med Chem 6:286–297PubMedCrossRefGoogle Scholar
  29. 29.
    Arner ES, Holmgren A (2006) The thioredoxin system in cancer. Semin Cancer Biol 16:420–426PubMedCrossRefGoogle Scholar
  30. 30.
    Conrad M (2009) Transgenic mouse models for the vital selenoenzymes cytosolic thioredoxin reductase, mitochondrial thioredoxin reductase and glutathione peroxidase 4. Biochim Biophys Acta 1790:1575–1585PubMedCrossRefGoogle Scholar
  31. 31.
    Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL (2006) Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 281:13005–13008PubMedCrossRefGoogle Scholar
  32. 32.
    Turanov AA, Kehr S, Marino SM, Yoo MH, Carlson BA, Hatfield DL, Gladyshev VN (2010) Mammalian thioredoxin reductase 1: roles in redox homoeostasis and characterization of cellular targets. Biochem J 430:285–293PubMedCrossRefGoogle Scholar
  33. 33.
    Mandal PK, Schneider M, Kolle P, Kuhlencordt P, Forster H, Beck H, Bornkamm GW, Conrad M (2010) Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. Cancer Res 70:9505–9514PubMedCrossRefGoogle Scholar
  34. 34.
    Anestal K, Prast-Nielsen S, Cenas N, Arner ES (2008) Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells. PLoS ONE 3:1–16CrossRefGoogle Scholar
  35. 35.
    Williams CH, Arscott LD, Muller S, Lennon BW, Ludwig ML, Wang PF, Veine DM, Becker K, Schirmer RH (2000) Thioredoxin reductase two modes of catalysis have evolved. Eur J Biochem 267:6110–6117PubMedCrossRefGoogle Scholar
  36. 36.
    Cheng Q, Sandalova T, Lindqvist Y, Arner ES (2009) Crystal structure and catalysis of the selenoprotein thioredoxin reductase 1. J Biol Chem 284:3998–4008PubMedCrossRefGoogle Scholar
  37. 37.
    Nordberg J, Zhong L, Holmgren A, Arner ES (1998) Mammalian thioredoxin reductase is irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue. J Biol Chem 273:10835–10842PubMedCrossRefGoogle Scholar
  38. 38.
    Papp LV, Lu J, Holmgren A, Khanna KK (2007) From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 9:775–806PubMedCrossRefGoogle Scholar
  39. 39.
    Witte AB, Anestal K, Jerremalm E, Ehrsson H, Arner ES (2005) Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 39:696–703PubMedCrossRefGoogle Scholar
  40. 40.
    Shyam K, Penketh PG, Divo AA, Loomis RH, Patton CL, Sartorelli AC (1990) Synthesis and evaluation of 1,2,2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents. J Med Chem 33:2259–2264PubMedCrossRefGoogle Scholar
  41. 41.
    Shyam K, Penketh PG, Loomis RH, Rose WC, Sartorelli AC (1996) Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-hydrazines. J Med Chem 39:796–801PubMedCrossRefGoogle Scholar
  42. 42.
    Kettenbach AN, Gerber SA (2011) Rapid and reproducible single-stage phosphopeptide enrichment of complex peptide mixtures: application to general and phosphotyrosine-specific phosphoproteomics experiments. Anal Chem 83:7635–7644PubMedCrossRefGoogle Scholar
  43. 43.
    Kettenbach AN, Schweppe DK, Faherty BK, Pechenick D, Pletnev AA, Gerber SA (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4:rs5PubMedCrossRefGoogle Scholar
  44. 44.
    Eng JK, McCormack AL, Yates JR (1994) An approach to correlate tandem mass-spectral data of peptides with amino-acid-sequences in a protein database. J Am Soc Mass Spectrom 5:976–989CrossRefGoogle Scholar
  45. 45.
    Faherty BK, Gerber SA (2010) MacroSEQUEST: efficient candidate-centric searching and high-resolution correlation analysis for large-scale proteomics data sets. Anal Chem 82:6821–6829PubMedCrossRefGoogle Scholar
  46. 46.
    Schallreuter KU, Gleason FK, Wood JM (1990) The mechanism of action of the nitrosourea anti-tumor drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase. Biochim Biophys Acta 1054:14–20PubMedCrossRefGoogle Scholar
  47. 47.
    Seyfried J, Wullner U (2007) Inhibition of thioredoxin reductase induces apoptosis in neuronal cell lines: role of glutathione and the MKK4/JNK pathway. Biochem Biophys Res Commun 359:759–764PubMedCrossRefGoogle Scholar
  48. 48.
    Lan L, Zhao F, Wang Y, Zeng H (2007) The mechanism of apoptosis induced by a novel thioredoxin reductase inhibitor in A549 cells: possible involvement of nuclear factor-kappaB-dependent pathway. Eur J Pharmacol 555:83–92PubMedCrossRefGoogle Scholar
  49. 49.
    Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 42:872–881PubMedCrossRefGoogle Scholar
  50. 50.
    Chin L, Andersen JN, Futreal PA (2011) Cancer genomics: from discovery science to personalized medicine. Nat Med 17:297–303PubMedCrossRefGoogle Scholar
  51. 51.
    Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Feau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ (2011) An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20:384–399PubMedCrossRefGoogle Scholar
  52. 52.
    Bednar F, Simeone DM (2012) Metformin and cancer stem cells: old drug, new targets. Cancer Prev Res (Phila) 5:351–354CrossRefGoogle Scholar
  53. 53.
    Arteaga CL, Baselga J (2012) Impact of genomics on personalized cancer medicine. Clin Cancer Res 18:612–618PubMedCrossRefGoogle Scholar
  54. 54.
    Lin SH, Kleinberg LR (2008) Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 8:343–359PubMedCrossRefGoogle Scholar
  55. 55.
    Penketh PG, Shyam K, Sartorelli AC (2000) Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas. Biochem Pharmacol 59:283–291PubMedCrossRefGoogle Scholar
  56. 56.
    Murren J, Modiano M, Kummar S, Clairmont C, Egorin M, Chu E, Sznol M (2005) A phase I and pharmacokinetic study of VNP40101 M, a new alkylating agent, in patients with advanced or metastatic cancer. Invest New Drugs 23:123–135PubMedCrossRefGoogle Scholar
  57. 57.
    Raizer J, Rice L, Rademaker A, Chandler J, Levy R, Muro K, Grimm S (2011) A phase I trial of laromustine (VNP40101 M) and temozolomide for patients with malignant gliomas in first relapse or progression. Neuro Oncol 13:60–61Google Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • Kevin P. Rice
    • 1
    Email author
  • Edmund J. Klinkerch
    • 1
  • Scott A. Gerber
    • 2
  • Tyler R. Schleicher
    • 1
    • 3
  • Tara J. Kraus
    • 1
  • Christopher M. Buros
    • 1
  1. 1.Department of ChemistryColby CollegeWatervilleUSA
  2. 2.Department of Genetics and BiochemistryGeisel School of Medicine at Dartmouth, One Medical Center DriveLebanonUSA
  3. 3.Department of Molecular and Cell BiologyUniversity of ConnecticutStorrsUSA

Personalised recommendations